Elena Uyy

Dr. Elena Uyy

Institute of Cellular Biology and Pathology "Nicolae Simionescu", Bucharest, Bucureşti, Romania
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2022 in Molecules
Verified
Journal Article
Open access
PDF file
EBElena G. Bernea
Elena G. Bernea
VSViorel Suica
Viorel Suica
EUElena Uyy
Elena Uyy
ACAurel Cerveanu-Hogas
Aurel Cerveanu-Hogas
RBRaluca M. Boteanu
Raluca M. Boteanu
FAFelicia Antohe
Felicia Antohe
Exosomes are small extracellular vesicles with a variable protein cargo in consonance with cell origin and pathophysiological conditions. Gestational diabetes mellitus (GDM) is characterized by different levels of chronic low-grade inflammation and vascular dysfunction; however, there are few data characterizing the serum exosomal protein cargo of GDM patients and associated signaling pathways. Eighteen pregnant women were enrolled in the study: 8 controls (CG) and 10 patients with GDM. Blood samples were collected from patients, for exosomes’ concentration. Protein abundance alterations were demonstrated by relative mass spectrometric analysis and their association with clinical parameters in GDM patients was performed using Pearson’s correlation analysis. The proteomics analysis revealed 78 significantly altered proteins when comparing GDM to CG, related to complement and coagulation cascades, platelet activation, prothrombotic factors and cholesterol metabolism. Down-regulation of Complement C3 (C3), Complement C5 (C5), C4-B (C4B), C4b-binding protein beta chain (C4BPB) and C4b-binding protein alpha chain (C4BPA), and up-regulation of C7, C9 and F12 were found in GDM. Our data indicated significant correlations between factors involved in the pathogenesis of GDM and clinical parameters that may improve the understanding of GDM pathophysiology. Data are available via ProteomeXchange with identifier PXD035673.

1 February 2017 in Journal of Proteomics
Verified
Journal Article
Closed access
RBRaluca M Boteanu
Raluca M Boteanu
VSViorel Suica
Viorel Suica
EUElena Uyy
Elena Uyy
LILuminita Ivan
Luminita Ivan
SDSimona O Dima
Simona O Dima
FAFelicia Antohe
Felicia Antohe

24 November 2011 in Cell and tissue research
Verified
Journal Article
Closed access
PDF file
RHRaluca Haraba
Raluca Haraba
VSViorel Suica
Viorel Suica
EUElena Uyy
Elena Uyy
LILuminita Ivan
Luminita Ivan
FAFelicia Antohe
Felicia Antohe

1 March 2010 in Microvascular Research
Verified
Journal Article
Closed access
EUElena Uyy
Elena Uyy
FAFelicia Antohe
Felicia Antohe
LILuminita Ivan
Luminita Ivan
RHRaluca Haraba
Raluca Haraba
DRDorel Lucian Radu
Dorel Lucian Radu
MSMaya Simionescu
Maya Simionescu

16 August 2016 in Journal of Proteome Research
Verified
Journal Article
Closed access
EUElena Uyy
Elena Uyy
VSViorel Suica
Viorel Suica
RBRaluca M. Boteanu
Raluca M. Boteanu
DMDana Manda
Dana Manda
ABAncuta E. Baciu
Ancuta E. Baciu
FAFelicia Antohe
Felicia Antohe

Verified
Journal Article
Open access
PDF file
RBRaluca Maria Boteanu
Raluca Maria Boteanu
VSViorel Suica
Viorel Suica
EUElena Uyy
Elena Uyy
LILuminita Ivan
Luminita Ivan
ACAurel Cerveanu-Hogas
Aurel Cerveanu-Hogas
FAFelicia Antohe
Felicia Antohe
Prognosis after myocardial infarction (MI) varies greatly depending on the extent of damaged area and the management of biological processes during recovery. Reportedly, the inhibition of the pro-inflammatory S100A9 reduces myocardial damage after MI. We hypothesize that a S100A9 blockade induces changes of major signaling pathways implicated in post-MI healing. Mass spectrometry-based proteomics and gene analyses of infarcted mice left ventricle were performed. The S100A9 blocker (ABR-23890) was given for 3 days after coronary ligation. At 3 and 7 days post-MI, ventricle samples were analyzed versus control and Sham-operated mice. Blockade of S100A9 modulated the expressed proteins involved in five biological processes: leukocyte cell–cell adhesion, regulation of the muscle cell apoptotic process, regulation of the intrinsic apoptotic signaling pathway, sarcomere organization and cardiac muscle hypertrophy. The blocker induced regulation of 36 proteins interacting with or targeted by the cellular tumor antigen p53, prevented myocardial compensatory hypertrophy, and reduced cardiac markers of post-ischemic stress. The blockade effect was prominent at day 7 post-MI when the quantitative features of the ventricle proteome were closer to controls. Blockade of S100A9 restores key biological processes altered post-MI. These processes could be valuable new pharmacological targets for the treatment of ischemic heart. Mass spectrometry data are available via ProteomeXchange with identifier PXD033683.